Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics Eiropas Savienība - latviešu - EMA (European Medicines Agency)

prepandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted) novartis vaccines and diagnostics

novartis vaccines and diagnostics s.r.l. - gripas vīrusa virsmas antigēnu (hemaglutinīna un neiraminidāzes) celma a/vjetnama/1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - vakcīnas - aktīvā imunizācija pret a gripas vīrusa h5n1 apakštipa. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.

Gumbohatch Eiropas Savienība - latviešu - EMA (European Medicines Agency)

gumbohatch

laboratorios hipra, s.a. - dzīvas novājinātas infekcijas bursal sērgas vīrusu (ibdv), celms 1052 - immunologicals par aves, vistas, dzīvu vīrusu vakcīnas, putnu infekcijas bursal sērgas vīrusu (gumboro slimība) - chicken; embryonated chicken eggs - aktīvās imunizācijas 1 dienu vecus broileru cāļus un embryonated broileru vistas olas, lai samazinātu klīniskās pazīmes un bojājumu bursa fabricius, ko izraisa ļoti bīstamu putnu infekcijas bursal slimības vīrusa infekcija.

Zulvac 1+8 Ovis Eiropas Savienība - latviešu - EMA (European Medicines Agency)

zulvac 1+8 ovis

zoetis belgium sa - inactivated bluetongue virus, serotype 1, strain btv-1/alg2006/01, inactivated bluetongue virus, serotype 8, strain btv-8/bel2006/02 - bluetongue virus, sheep, inactivated viral vaccines - aitas - aitu imunizācija no 1. 5 mēnešu vecumā, lai novērstu infekciozā katarālā drudža vīrusa izraisītu viremiju, 1. un 8. serotipu. imūnsistēmas sākums: 21 diena pēc primārās vakcinācijas shēmas pabeigšanas. imunitātes ilgums: 12 mēneši.

Vectormune FP ILT + AE Eiropas Savienība - latviešu - EMA (European Medicines Agency)

vectormune fp ilt + ae

ceva-phylaxia co. ltd. - live recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus (rfp-lt) and avian encephalomyelitis virus, strain calnek 1143 (ae) - immunologicals for aves, live viral vaccines, domestic fowl - cālis - for active immunisation of chickens of 8 to 13 weeks of age in order to reduce the skin lesions due to fowlpox, to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis and to prevent egg production losses due to avian encephalomyelitis.

Vectormune FP ILT Eiropas Savienība - latviešu - EMA (European Medicines Agency)

vectormune fp ilt

ceva-phylaxia co. ltd. - recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus, live - cālis - for active immunisation of chickens from 8 weeks of age in order to reduce the skin lesions due to fowlpox and to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis.

Innovax-ND-ILT Eiropas Savienība - latviešu - EMA (European Medicines Agency)

innovax-nd-ilt

intervet international b.v. - cell-associated live recombinant turkey herpesvirus (strain hvt/ndv/ilt) expressing the fusion protein of newcastle disease virus and the glycoproteins gd and gi of infectious laryngotracheitis virus - imunoloģisks aves - embryonated chicken eggs; chicken - for active immunisation of one-day-old chicks or embryonated chicken eggs:to reduce mortality and clinical signs caused by newcastle disease (nd) virus,to reduce mortality, clinical signs and lesions caused by avian infectious laryngotracheitis (ilt) virus and marek’s disease (md) virus.

Eravac Eiropas Savienība - latviešu - EMA (European Medicines Agency)

eravac

laboratorios hipra, s.a. - inactivated rabbit haemorrhagic disease type 2 virus (rhdv2), strainv-1037 - inaktivētu vīrusu vakcīnām - truši - aktīvās imunizācijas truši, kas vecāki par 30 dienām, lai samazinātu mirstību, ko izraisa trušu hemorāģiskās slimības, 2. tipa vīruss (rhdv2).

Ultifend ND IBD Eiropas Savienība - latviešu - EMA (European Medicines Agency)

ultifend nd ibd

ceva-phylaxia veterinary biologicals co. ltd - turkey herpes virus, strain rhvt/nd/ibd, expressing the fusion protein of newcastle disease virus and the vp2 protein of infectious bursal disease virus, live recombinant - imunoloģisks aves - embryonated chicken eggs; chicken - for the active immunisation of one-day-old chicks or 18-day-old chicken embryonated eggs to reduce mortality, clinical signs and lesions caused by newcastle disease virus (ndv) and to reduce virus shedding; to reduce mortality, clinical signs and bursa lesions caused by very virulent infectious bursal disease virus (ibdv); to reduce mortality, clinical signs and lesions caused by classical marek’s disease virus (mdv).

Suvaxyn Circo+MH RTU Eiropas Savienība - latviešu - EMA (European Medicines Agency)

suvaxyn circo+mh rtu

zoetis belgium sa - inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2 orf2 protein, inactivated mycoplasma hyopneumoniae, strain p-5722-3 - inaktivēta inaktivētu vīrusu un baktēriju vakcīnas - cūkas - aktīvās imunizācijas cūkas no 3 nedēļu vecuma, pret cūku circovirus tips 2 (pcv2) samazināt vīrusu slodzi asins un limfoīdo audu un fekāliju atlaišanu, ko izraisa infekcija pcv2. aktīvai cūku imunizācijai, kas vecāka par 3 nedēļām, pret mycoplasma hyopneumoniae, lai samazinātu plaušu bojājumus, ko izraisa m. hyopneumoniae.

Respiporc FLUpan H1N1 Eiropas Savienība - latviešu - EMA (European Medicines Agency)

respiporc flupan h1n1

ceva santé animale - influenza a virus/human strain: a/jena/vi5258/2009 (h1n1)pdm09, inactivated - imunoloģiskie līdzekļi, inaktivētas vīrusu vakcīnas cūkām, cūku gripas vīruss - cūkas - cūku aktīvā imunizācija no 8 nedēļu vecuma pret cūku gripas pandēmijas h1n1 vīrusu, lai samazinātu plaušu vīrusu slodzi un vīrusu izdalīšanos. the vaccine can be used during pregnancy up to three weeks before expected farrowing and during lactation lactation.